Search Result

Results for "

CPI

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) ADC Payload (1) Adenosine Receptor (3) Aminopeptidase (2) Apoptosis (3) Bacterial (1) Carnitine Palmitoyltransferase (CPT) (1) CD73 (1) CTLA-4 (1) Epigenetic Reader Domain (8) Fungal (1) Histone Acetyltransferase (6) Histone Demethylase (4) Histone Methyltransferase (3) Itk (1) LAG-3 (1) Ligands for Target Protein for PROTAC (1) Mitochondrial Metabolism (1) P-glycoprotein (1) PD-1/PD-L1 (1) Peptide-Drug Conjugates (PDCs) (2) PROTACs (1) Reference Standards (3) Target Protein Ligand-Linker Conjugates (2) TNF Receptor (1)
By Research Areas:	Cancer (31) Infection (3) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12863

Pelabresib CPI-0610	Epigenetic Reader Domain	Cancer
Pelabresib (CPI-0610) is a potent, selective, orally active and cell-active BET inhibitor. Pelabresib inhibits BRD4-BD1 with an IC₅₀ of 39 nM, and with an EC₅₀ value of 0.18 μM for MYC .

HY-15453

Devimistat Maximum Cited Publications 23 Publications Verification CPI-613	Apoptosis Mitochondrial Metabolism	Cancer
Devimistat is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells .

HY-100421

CPI-455 10+ Cited Publications	Histone Demethylase	Cancer
CPI-455 is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-101978

Ciforadenant 5+ Cited Publications CPI-444; V81444	Adenosine Receptor	Cancer
Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses .

HY-150298

Soquelitinib 3 Publications Verification CPI-818	Itk	Inflammation/Immunology Cancer
Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 ⁺ cells that possess enhanced T effector function .

HY-145602

Tulmimetostat CPI-0209	Histone Methyltransferase	Cancer
Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor that targets and inhibits the EZH2 enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies .

HY-15846

CPI-203 5+ Cited Publications	Epigenetic Reader Domain Apoptosis	Cancer
CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC₅₀ value of appr 37 nM (BRD4 α-screen assay).

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-100482

CPI-637 10+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CPI-637 is a selective and potent CBP/EP300 bromodomain inhibitor with IC₅₀ values of 0.03 μM, 0.051 μM and 11.0 μM for CBP, EP300 and BRD4 BD-1, respectively, and an EC₅₀ of 0.3 μM for CBP .

HY-100421A

CPI-455 hydrochloride 10+ Cited Publications	Histone Demethylase	Cancer
CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-P10856

CPI1	P-glycoprotein	Cancer
CPI1 is a multidrug resistance protein 1 (MRP1) inhibitor with a K_i value of 100 nM. CPI1 binds to the same substrate-binding site as leukotriene C₄, stabilizes MRP1 in an apo-like inward-facing conformation, blocks the conformational changes required for ATP hydrolysis and substrate transport, and inhibits the ATPase activity of human and bovine MRP1. CPI1 serves as a tool for investigating the substrate transport mechanism of MRP1. CPI1 is applicable to research related to cancer multidrug resistance .

HY-P99181

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology Cancer
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

HY-102024

A2A receptor antagonist 1 CPI-444 analog	Adenosine Receptor	Neurological Disease Cancer
A2A receptor antagonist 1 (CPI-444 analog) is an antagonist of both adenosine A_2A receptor and A₁ receptor with K_i values of 4 and 264 nM, respectively .

HY-42429

CPI-203-PEG1-C3-O-COOH	Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain	Cancer
CPI-203-PEG1-C3-O-COOH is a conjugate of the BRD4 ligand (HY-78695) and the linker (HY-42427). CPI-203-PEG1-C3-O-COOH can be used for synthesizing PROTAC BRD4 degrader ARV-771 (HY-100972) .

HY-123419

CPI-4203	Histone Demethylase	Cancer
CPI-4203 is a potent KDM5A inhibitor with an IC₅₀ of 250 nM. CPI-4203 is competitive with 2-oxoglutarate (2-OG). CPI-4203 is structurally related to CPI-455 (HY-100421) but is less potent .

HY-100376

CPI-1189	TNF Receptor Apoptosis	Infection Neurological Disease
CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases .

HY-129379

DC0-NH2	ADC Payload	Cancer
DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component .

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

HY-12863B

CPI-0610 carboxylic acid	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CPI-0610 carboxylic acid is a ligand for target protein for PROTACT. CPI-0610 carboxylic acid is a potent bromodomain and extra-terminal (BET) protein inhibitor. CPI-0610 carboxylic acid has the potential in the therapy of multiple myeloma .

HY-134899

CPI-1328	Histone Methyltransferase	Cancer
CPI-1328 is an EZH2 inhibitor with a K_i value of 63 fM.

HY-15846A

*(Rac)-CPI-203*	Epigenetic Reader Domain	Cancer
(Rac)-CPI-203 is a racemate of CPI-203 (HY-15846) (BET bromodomain inhibitor)

HY-16149

*SDZ-CPI* 975** CPI-975	Carnitine Palmitoyltransferase (CPT) Acyltransferase	Metabolic Disease
SDZ-CPI-975 is a novel, reversible, and selective CPT I inhibitor. SDZ-CPI-975 effectively inhibits fatty acid oxidation and lowers blood glucose levels .

HY-111085

CPI-905	Histone Methyltransferase	Cancer
CPI-905 is a potent, selective, and cell-active EZH2 inhibitor .

HY-136285A

*(R,R)-CPI-1612*	Histone Acetyltransferase	Cancer
(R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-145386

*(S,S)-CPI-1612*	Histone Acetyltransferase	Cancer
(S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-120196

CPI703	Epigenetic Reader Domain	Cancer
CPI703, a BRD inhibitor, binds with residues in domain1 of 5DBM complex .

HY-109706

*(Rac)-CPI-098*	Bacterial Fungal	Infection
(Rac)-CPI-098 shows antibacterial activity. (Rac)-CPI-098 exhibits superior anti-fungal activity against Monascus ruber, better activity against Aspergillus fumigates, good activity against Aspergillus niger and Aspergillus parasites and moderate activity against Candida albicans .

HY-161250

*Pomalidomide-NH-PEG6-amide-C2-CPI-1612*	PROTACs	Cancer
Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a DC₅₀ of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells .

HY-159777

JQ-1-PEG5-Alkyne	Target Protein Ligand-Linker Conjugates	Cancer
CPI-203-PEG5-Alkyne is a conjugate of target protein ligase and linker. CPI-203-PEG5-Alkyne can be used for synthesis of PROTAC BRD4-DCAF1 degrader-1 (HY-169151) .

HY-106154

DTS-201	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 (CPI-0004) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

HY-122081

CPI-644	Histone Acetyltransferase LAG-3 CTLA-4 PD-1/PD-L1	Cancer
CPI-644 is a selective EP300/CBP bromodomain inhibitor, with an IC₅₀ of 0.18 µM against the CBP bromodomain. CPI-644 reduces the proportion of FOXP3 ⁺cells and downregulates the expression of LAG-3, CTLA-4 and PD-1. CPI-644 can be used in cancer-related research .

HY-100421R

CPI-455 (Standard)	Histone Demethylase Reference Standards	Cancer
CPI-455 (Standard) is the analytical standard of CPI-455 (HY-100421). This product is intended for research and analytical applications. CPI-455 is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-100482R

CPI-637 (Standard)	Epigenetic Reader Domain Reference Standards Histone Acetyltransferase	Cancer
CPI-637 (Standard) is the analytical standard of CPI-637 (HY-100482). This product is intended for research and analytical applications. CPI-637 is a selective and potent CBP/EP300 bromodomain inhibitor with IC50 values of 0.03 μM, 0.051 μM and 11.0 μM for CBP, EP300 and BRD4 BD-1, respectively, and an EC50 of 0.3 μM for CBP .

HY-101978R

Ciforadenant (Standard) CPI-444 (Standard); V81444 (Standard)	Reference Standards Adenosine Receptor	Cancer
Ciforadenant (Standard) is the analytical standard of Ciforadenant (HY-101978). This product is intended for research and analytical applications. Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses .

Cat. No.	Product Name	Target	Research Area

HY-P10856

CPI1	P-glycoprotein	Cancer
CPI1 is a multidrug resistance protein 1 (MRP1) inhibitor with a K_i value of 100 nM. CPI1 binds to the same substrate-binding site as leukotriene C₄, stabilizes MRP1 in an apo-like inward-facing conformation, blocks the conformational changes required for ATP hydrolysis and substrate transport, and inhibits the ATPase activity of human and bovine MRP1. CPI1 serves as a tool for investigating the substrate transport mechanism of MRP1. CPI1 is applicable to research related to cancer multidrug resistance .

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99181

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology Cancer
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

Species:	Human (1) Mouse (1)
Tag:	His (2)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71229

	PPP1R14A Protein, Human (His) Protein Phosphatase 1 Regulatory Subunit 14A; 17 kDa PKC-Potentiated Inhibitory Protein of PP1; Protein Kinase C-Potentiated Inhibitor Protein of 17 kDa; CPI-17; PPP1R14A; CPI17; PPP1INL	Human	E. coli
	The PPP1R14A protein is a key cellular regulator that effectively inhibits PPP1CA and exhibits significant activity amplification upon phosphorylation. This phosphorylation-induced transformation turns PPP1R14A into a dynamic molecular switch adept at regulating PPP1CA substrate phosphorylation. PPP1R14A Protein, Human (His) is the recombinant human-derived PPP1R14A protein, expressed by E. coli , with C-6*His labeled tag.

HY-P70137

	Cystatin B/CSTB Protein, Mouse (His) rMuCystatin-B, His; CPI-B; CST6cystatin B (liver thiol proteinase inhibitor)10STFBcystatin-B; CSTB; cystatin B (stefinB); Cystatin B; EPM1; Liver thiol proteinase inhibitor; PME; Stefin B; stefin-B	Mouse	E. coli
	Cystatin B/CSTB Protein, an intracellular thiol proteinase inhibitor, crucially regulates proteolytic activities within the cell. By inhibiting thiol proteinases, Cystatin B maintains the balance of proteolytic processes, emphasizing its significance in cellular homeostasis. Its inhibitory function underscores involvement in cellular processes requiring precise regulation of proteolytic activity for normal cellular function and integrity. Cystatin B/CSTB Protein, Mouse (His) is the recombinant mouse-derived Cystatin B/CSTB protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Rabbit (2)
Reactivity:	Human (2) Rat (2)
Application:	IHC-P (2) WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1) Recombinant (1)
Modification:	Unmodified (1)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83104

	Cystatin B Antibody (YA2849) CSTB; CST6; STFB; Cystatin-B; CPI-B; Liver thiol proteinase inhibitor; Stefin-B	WB, IHC-P	Human, Rat
	Cystatin B Antibody (YA2849) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cystatin B.

HY-P83104A

	Cystatin B Antibody (YA2849)(PBS only) CSTB; CST6; STFB; Cystatin-B; CPI-B; Liver thiol proteinase inhibitor; Stefin-B	WB, IHC-P	Human, Rat
	Cystatin B Antibody (YA2849) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cystatin B.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-159777

JQ-1-PEG5-Alkyne		Alkynes
CPI-203-PEG5-Alkyne is a conjugate of target protein ligase and linker. CPI-203-PEG5-Alkyne can be used for synthesis of PROTAC BRD4-DCAF1 degrader-1 (HY-169151) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: